The European Medicines Agency (EMEA) assembled for the first time European and international experts from academia, regulatory authorities (from Europe, Japan and the USA) and pharmaceutical industry, in a workshop this week, to review opportunities and difficulties in developing stem cell-based therapies and to discuss regulatory challenges.
The workshop was part of the public consultation process on the first dedicated regulatory guidance document on stem-cell research and development. The draft reflection paper builds upon the experience gained so far through extensive dialogue with European experts and pharmaceutical industry and was developed by the Agency's Committee for Advanced Therapies (CAT), together with the Cell-based Products Working Party and Biologics Working Party. "Today's discussion will pave the way for the first European marketing authorisation application for a stem cell-based product," commented Thomas Lonngren, Executive Director of the EMEA.
Dramatic rise in stem cell-based research
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze